RIPK1 and central nervous system cancer: Regarding the expression of RIPK1 in the samples derived from patients with different subtypes of glioma, our results showed higher levels of RIPK1 in the samples derived from patients with GBM and astrocytoma CNS (central nervous system) grade 2–3 (A2-3) compared with the samples of low-grade gliomas, such as oligodendrogliomas (ODs) and wtIDH gliomas grade 2–3 (OA) (Figure 1B).